Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A
Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.
Bibliographic details
O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. ClinicoEconomics and Outcomes Research 2013; 5: 459-470